Celebrating the Biochemical Society’s impact in 2024
News, Mar 27 2025
Our activities are inspired by our core objectives and EDI principles and throughout 2024 we celebrated many achievements and milestones, from grants and awards to events and publishing.
We’re delighted to share a new webpage to highlight the efforts we have undertaken and acknowledge the outstanding work that has taken place across our community.
Some of our 2024 highlights have been shared below. To learn more about the vital work we undertook and the impact our activities had last year, visit our new impact page.
In 2024 we said goodbye to Kate Baillie, who had been CEO for more than 12 years, and we welcomed Phil Morgan as our new CEO in December.
We supported our Local Ambassadors with over £2,700 in Recruitment Grants and supported five public engagement events, reaching audiences across all career stages.
Our diverse grants programme introduced a new scheme, Lab Visit Grants, and we awarded over £9,000 to support projects addressing issues relating to inclusion and diversity in science.
We recognised 14 prestigious winners in the Biochemical Society 2024 Awards. Following the introduction of a new streamlined nominations process, we also announced five new categories.
We held 15 webinars in 2024, as part of our dedicated Biochemistry Focus webinar series. Of these, Computer-Aided Drug Design: Types, Uses and Opportunities was the highest viewed and we were delighted to share Dr Emma Yhnell, the first winner of the Teaching Excellence Award – Early Career’s webinar ‘Why I treat every lecture like a performance.’
Our varied events programme welcomed over 1.7k delegates from 59 countries and introduced new events in 2024 on topics covering PINK1, glycobiology and introduction to statistics.
We achieved over 5.2 million worldwide article views in 2024 across our journals. We’re also proud to have continued our commitment to open science, welcoming 336 institutions who signed an R&P agreement with us.
We look forward to a productive 2025 and continuing to support our community across the molecular biosciences.
